Travere Therapeutics announced on Tuesday that it has entered into a licensing agreement with private biotech firm Everest Medicines to develop and commercialize an experimental drug for kidney disease, in a deal valued at up to $1.14 billion.
- Under the agreement, Travere will hold exclusive rights to develop and commercialize civorebrutinib outside China and certain parts of East and Southeast Asia.
- Everest Medicines will receive $112.5 million upfront, along with up to approximately $1.03 billion in additional payments tied to development, regulatory, and sales milestones, as well as royalties from future sales.
- Civorebrutinib, also known as EVER001, is an oral drug currently being evaluated for rare immune-driven kidney diseases.
- Travere Therapeutics already markets two FDA-approved kidney treatments: Filspari, used for IgA nephropathy and focal segmental glomerulosclerosis, and Thiola, used for cystinuria.
- The company plans to study civorebrutinib across multiple rare kidney conditions, including primary membranous nephropathy, FSGS, and minimal change disease.
- The drug is a BTK inhibitor designed to block B-cell signaling, thereby reducing harmful antibody production that can lead to kidney inflammation and damage. Travere also noted that civorebrutinib has been generally well tolerated in studies so far.
About Travere Therapeutics
Travere Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare kidney diseases and other serious conditions. The company is known for its approved therapies such as Filspari for IgA nephropathy and focal segmental glomerulosclerosis, and Thiola for cystinuria. Travere continues to expand its pipeline of innovative drugs aimed at addressing unmet medical needs in nephrology and improving outcomes for patients with rare and chronic kidney disorders.
